

1 **Regulation of aged skeletal muscle regeneration by circulating extracellular**
 2 **vesicles**


3
 4 Amrita Sahu^{1,2}, Zachary J. Clemens², Sunita N. Shinde¹, Sruthi Sivakumar^{1,3}, Abish Pius^{1,4},
 5 Ankit Bhatia⁵, Silvia Picciolini⁶, Cristiano Carlomagno⁶, Alice Gualerzi⁶, Marzia Bedoni⁶,
 6 Bennett Van Houten⁷, Mita Lovalekar⁸, Nicholas F. Fitz², Iliya Lefterov², Aaron Barchowsky^{2,7},
 7 Radosveta Koldamova², *Fabrisia Ambrosio^{1,2,3,9}

8
 9 *Corresponding author

10

11 **SUPPLEMENTARY FIGURES**


12




13

14 **Supplementary Figure 1. Effect of EV depletion on myogenicity and cellular proliferation. a,**
 15 **Representative images of MyoD and Desmin expression in aged MPCs when treated with aged or young**
 16 **serum depleted of EVs. Scale: 50 μ m. b, NTA plot of young serum vs. EV-depleted young serum (left)**
 17 **and fetal bovine serum (FBS), and FBS-free media (OptiMEM) and DMEM (right). c, Quantification of**
 18 **ki67+(%) aged MPCs in response to young serum, aged serum, or EV-depleted young or aged serum**
 19 **(*p<0.05, one-way ANOVA with Tukey's comparison, n=3 wells/group). Data presented as mean +**
 20 **SEM.**


21



Supplemental Figure 2. Serum treatment increased target cell mitochondrial health in an age- and EV-dependent manner **a**, Quantification of SDHA in aged MPCs receiving serum treatments with or without EVs at timepoints: 30 minutes, 6 hours, 24 hours, and 48 hours. (** $p < 0.01$, # $p < 0.0001$, two-way ANOVA with Dunn's multiple comparisons to young serum as control). **b**, Fibro-adipogenic progenitor cells (FAPs) were exposed to young or aged serum with/without EVs for 48 hours, and bioenergetics was assessed using Seahorse XFe96 analyzer. Eight wells were evaluated for bioenergetics per cell type and treatment group. Oxygen Consumption Rate (OCR) is represented as the average of the three time points for Basal, Oligomycin treatment, FCCP treatment, 2DG treatment and Rotenone treatment \pm SEM (8 wells/group, data points represent $n=3$ time points, * $p \leq 0.05$, ** $p < 0.01$, *** $p < 0.001$, # $p < 0.0001$; two-way ANOVA with repeated measures and Tukey's multiple comparisons). Data presented as mean + SEM.




Supplemental Figure 3. Cells treated with young serum depleted of EVs display decreased MyoD expression, but the effect is reversed when serum is replenished with isolated EVs. Removal of EVs from young serum significantly reduced the MyoD expression of aged myogenic progenitor cells. However, supplementation of the EV-depleted serum with purified column-derived EVs enhanced MyoD expression of target muscle cells. (* $p < 0.05$, *** $p < 0.001$, **** $p < 0.0001$, $n=3$ wells/group, one-way ANOVA with Tukey's multiple comparison). Data presented as mean + SEM.




50
51
52
53
54
55
56
57
58
59
60

Supplemental Figure 4. Characterization and protein quantification of circulating EVs in young and aged serum. **a**, In-well immunofluorescence western analysis of young serum EVs reveals the presence of EV surface markers, CD63 and CD81, and absence of cytosolic contaminant protein, GM130. CD63 and CD81 intensity scores were divided by final EV concentrations in the wells and normalized to average intensity of surface markers of young serum EVs. (NC=negative control). **b**, Bicinchoninic acid assay was used to quantify the protein content per EV ($p>0.05$, two-tailed Student's t test with Welch's correction). Data presented as mean + SEM.



61
62
63
64
65
66
67
68
69
70
71

Supplemental Figure 5. The decreased MyoD expression in cells treated with young EV-depleted serum is restored when serum is repleted with either isolated EVs (Depleted serum+ EVs) or Exoquick elute (Depleted serum+EQ EVs). Removal of EVs from young serum significantly reduced the MyoD expression of aged myogenic progenitor cells. However, supplementation of the EV-depleted serum with purified column-derived EVs or Exo-quick precipitated EVs equally enhanced MyoD expression of target muscle cells. (** $p<0.01$, $n=3$ wells/group, one-way ANOVA with Tukey's multiple comparison). Data presented as mean + SEM.




72

73 **Supplemental Figure 6. MyoD expression and cardiolipin content in aged muscle cells is increased**
 74 **in the presence of young serum in an EV-dependent manner.** **a**, Quantification of MyoD *in vivo* three
 75 days post injury in aged animals receiving sham, young serum, or EV-depleted young serum treatment.
 76 (* $p < 0.05$, one-way ANOVA with Tukey's multiple comparisons, $n = 4/\text{group}$). **b**, Representative images
 77 of MyoD in aged MPCs treated with young or aged serum EVs. Scale: 50 μm . **c**, Representative image of
 78 MyoD in Young MPCs. Scale: 50 μm . **d**, Representative images of cardiolipin content in aged MPCs
 79 treated with young or aged serum EVs. Scale: 50 μm . Data presented as mean + SEM.

80

81



82

83 **Supplemental Figure 7.** Representative images of Klotho protein in *Klotho*^{-/-} MPCs or aged MPCs
 84 administered with young serum EVs treated with a non-targeting RNA (scramble) or silencing RNA
 85 (siRNA) to *Klotho*. Scale: 50 μm.

86

87

88

89


90

91


92

93

94



96
97
98
99
100
101
102



104

105 **Supplemental Figure 8. Correlation matrices of EV structural and compositional features.** (A)
 106 Pearson r coefficients were evaluated for correlation between features extracted from the dataset. Size
 107 (area and aspect ratio) and texture (modulation) features were extracted from the ImageStream image-
 108 files using IDEAS software. Modulation in the context of fluorescent images refers to dispersion or
 109 accumulation of the tagged protein of interest within the region of interest. The intensity feature was
 110 evaluated using classical computer vision-based image processing. (B) Pearson r coefficients were
 111 evaluated for correlation of Klotho mRNA intensity with size and intensity features of bright-field, side-
 112 scatter, PKH26, CD63, and CD81 channels. Size (area and aspect ratio) features were extracted from the

113 ImageStream image-files using IDEAS software. The intensity feature was evaluated using classical
114 computer vision-based image processing. From the filtered dataset of 13,206 total particles, 130 particles
115 that satisfied the criteria of total klotho<15 and cd81>150, were eliminated for correlation matrix as they
116 were observed to be in the noise range when plotted. The p-values for each correlation is indicated in
117 brackets below the Pearson r coefficients.

118

119

120

121

122

123


124

125

126

127


128



129

130 **Supplemental Figure 9. Administration of EVs from $Klotho^{+/-}$ animals ultimately regulates *in vivo***
 131 **muscle SDHA expression, a small portion of which express kidney marker, podocin. a,**
 132 Quantification of the number of Klotho mRNA positive EVs that are positive for kidney marker, podocin
 133 (%), as determined by imaging flow cytometry. **b**, Violin plots of Klotho mRNA intensity values per EV,
 134 extracted using imaging flow cytometry analysis of EVs ($p < 0.0001$, $n = 19,992$ ($Klotho^{+/+}$), 38,524
 135 ($Klotho^{+/-}$) EVs for this experimental run were pooled from 4 young or 4 aged serum samples; Mann
 136 Whitney t test, experiment repeated in triplicates). Violin plot minima, maxima, median, 25th percentile
 137 and 75th percentile are 0, 16530.5, 0, 0, 78.8 for $Klotho^{+/+}$ EVs and 0, 991.2, 0, 0, and 32.6 for $Klotho^{+/-}$
 138 EVs. Quantification of **c**, CD63 and **d**, CD81 content per EV in the circulation of $Klotho^{+/+}$ or $Klotho^{+/-}$
 139 animals ($p > 0.05$, $n = 3$ /group, two-tailed Mann Whitney t test). **e**, Quantification of EV concentration in
 140 circulation of $Klotho^{+/+}$ or $Klotho^{+/-}$ animals ($p > 0.05$, $n = 9$ /group, two-tailed Welch's t test). **f**, Violin plots
 141 of Klotho protein intensity values extracted using imaging flow cytometry analysis of EVs ($p < 0.0001$,
 142 $n = 19,992$ ($Klotho^{+/+}$), 38,577 ($Klotho^{+/-}$) EVs for this experimental run, pooled from 4 young or 4 aged
 143 serum samples, two-tailed Mann Whitney t test, experiment repeated in triplicates). Violin plot minima,
 144 maxima, median, 25th percentile and 75th percentile are 0, 765296.2, 95.4, 0, and 1797.4 for $Klotho^{+/+}$ EVs
 145 and 0, 1310203.4, 2715.4, 152.1, and 5759.9 for $Klotho^{+/-}$ EVs. **g**, Representative images of SDHA content
 146 in injured aged muscles 14dpi, treated with EVs isolated from $Klotho^{+/+}$ or $Klotho^{+/-}$ serum. Scale: 50
 147 μ m. Data presented as mean + SEM.

148
149
150
151
152
153
154
155
156



157 **Supplemental Figure 10. Histogram and kernel density plot for overall muscle endurance of aged**
 158 **animals one day post injury.** Variability in the overall muscle endurance as determined by the hanging
 159 grid test as observed at one-day post injury (1 dpi) when normalized to baseline, pre-injury scores. Only
 160 animals performing within 25-75% percentile of the median (range:0.40-0.74) were included in the study.

161
162
163
164
165
166
167

Study accession	Number of samples	Sample type	Isolation method	RNA isolation	Age	Sex
GSE100206	32	plasma	Total exosome isolation kit from Invitrogen	exoRNeasy Serum/Plasma Maxi kit	Not collected	Not specified

168

169 **Supplemental Table 1. Table outlining sample demographic information and methods**
 170 **summary of publicly archived RNAseq data used for quantification of Klotho transcripts**
 171 **within circulating EVs.** The Klotho transcript values shown in Figure 3I were obtained from
 172 www.exorbase.org.

173
174

175 SUPPLEMENTARY METHODS

176 *Animal experimentation*

177 All animal experiments were performed with prior approval from the Institutional Animal
178 Care and Use Committee of the University of Pittsburgh (IACUC protocol # 20087744,
179 20098045). Aged male C57BL/6 mice used in these studies were obtained from NIA (21-24
180 months). Young male C57/BL6 mice were obtained from Jackson Laboratories. The original
181 breeders for Klotho strain mice were obtained from MMRCC, UC Davis. The mouse colony for
182 the laboratory was maintained in house. *Klotho* homozygotes (3-6 months, *Klotho*^{+/+}, B6; 129S5-
183 *Kltm1-Lex*), *Klotho* heterozygotes (3-6 months, *Klotho*^{+/-}; B6; 129S5-*Kltm1-Lex*), young, and
184 aged male mice were used to obtain EVs from serum. *Klotho* knockout (4-6 weeks, *Klotho*^{-/-}; B6;
185 129S5-*Kltm1-Lex*), young, and aged male mice were used to isolate muscle progenitor cells
186 (MPCs).

187

188 *Muscle progenitor cell (MPC) isolation*

189 Muscle progenitor cells were isolated as previously described¹. Briefly, hindlimb muscles
190 were harvested and minced, after which time the tissue homogenate was weighed and treated
191 with successive digestive enzymes. The homogenate was digested in 2 mg/mL of collagenase XI
192 for one hour, followed by 2.4 U/mL dispase for 45 minutes and 0.1% trypsin for 30 minutes. The
193 final homogenate was then centrifuged at 500 g for 5 minutes at 8°C, after which time the final
194 pellet was re-suspended in high serum medium (Dulbecco's modified eagle's medium, 20% fetal
195 bovine serum, 1% penicillin/streptomycin and 0.5% chick embryo extract). The suspension was
196 then plated in collagen I-coated plates for 24 hours, after which time the supernatant was
197 transferred to another collagen coated plate. For *in vitro* experiments, MPCs were freshly
198 isolated and were not used beyond two passages. Expression levels of Pax7 and MyoD in
199 isolated MPCs were confirmed to be 82% and 97%, respectively.

200

201 *Fibro-adipogenic progenitor isolation*

202 Hindlimb muscles were isolated from aged mice and were washed in HBSS to remove any
203 hair, debris or blot clots. Muscles were chopped in wash media (HBSS+10% horse
204 serum+1% pen/strep) until the suspension could pass through a 10 mL pipette. The muscle
205 suspension was transferred into a 50 mL tube and centrifuged at 900g, 8°C for five minutes. The

206 muscles went through a successive digestion process of 750U/mL collagenase II (1.5 hours-step
207 1), 11 U/mL dispase and 1000 U/mL collagenase II (both together for 45 minutes-step 2). A
208 modified flow cytometry protocol was applied to isolate FAPs². Cells were sorted as CD31⁻
209 (Fisher Scientific, cat#50-951-7), CD45⁻ (Invitrogen, cat# 11-0451-82), Sca1⁺(Invitrogen,
210 cat#25-5981-82) and α -7 integrin⁻ (Invitrogen, cat# MA5-23555) population and grown in high
211 serum media (Dulbecco's modified eagle's medium, 20% fetal bovine serum, 1%
212 penicillin/streptomycin and 0.5% chick embryo extract).

213

214 *Serum collection*

215 Blood was extracted from animals placed in supine position using the cardiac puncture
216 method. Briefly, animals were anesthetized using isofluorane. Then, the skin was cut from the
217 abdomen to the neck. The diaphragm was cut open for easy access to the apex of the heart. A
218 pair of mosquito scissors were used to pull open the chest cavity. Blood was then drawn from the
219 apex of the heart using a 25 5/8 gauge 1 mL needle. To avoid hemolysis due to shear stress,
220 blood was then placed into a 1.5mL Eppendorf tube after removing the needle from the syringe.
221 Blood was centrifuged for 20 minutes at 16,100 g after incubation at room temperature for 60
222 minutes. The serum was then aliquoted into 1.5 mL centrifuge tubes (Eppendorf) using a 200 μ L
223 micro-pipette and were preserved in the -20°C freezer for subsequent use. Any samples
224 displaying hemolysis (as evidenced by significant pink/red coloration) were not included in the
225 experiment.

226

227 *Administration of serum on cells*

228 Aged MPCs were plated at a density of 8,000 or 10,000 cells per well in an 8-well chamber
229 slide or at 60,000 cells per well in a 6-well plate. Fibro-adipogenic progenitors (FAPs) were
230 plated at a density of 60,000 cells per well in a 6-well plate. Cells were cultured for 24 hours and
231 then treated with 10% young or aged serum in FBS-free media (optiMEM) with or without EVs
232 for 48 hours prior to performing any end-point analysis.

233

234 *Depletion of EVs from serum*

235 Bulk EVs were depleted from young and aged serum using ExoQuick (Product# EXOQ5A-
236 1) following the manufacturer's recommended protocol. Briefly, 63 μ L of Exoquick solution was

237 added to 250 μ L serum and the mixture was incubated on ice for 30 minutes. Next, samples were
238 centrifuged at 1500 g for 30 minutes at 4C. The EVs were pelleted at the bottom of the tube and
239 the EV-free serum was used for *in vitro* applications. Exoquick removed >95% EVs from the
240 blood serum (Supplemental Fig. 2).

241

242 ***Analysis of bioenergetics***

243 Muscle progenitors or FAPs were first cultured for 24 hours on 6-well plates at a density of
244 60,000 cells per well, after which time they were treated with young serum, aged serum, or EV-
245 depleted young or aged serum. The cells were trypsinized 48 hours after treatment and plated on
246 a 96-well plate at a density of 30,000 cells per well using CellTak. The cells were then cultured
247 in un-buffered DMEM for 1 hour at 37°C without CO₂. Cells were exposed to stressors with
248 successive injections of 1 μ M Oligomycin, 300 nM FCCP (Carbonyl cyanide-4-
249 (trifluoromethoxy)phenylhydrazine), 100 mM 2-DG (2-Deoxy-D-glucose) and 1 μ M Rotenone.
250 The average of the first three time points prior to oligomycin treatment were averaged to get the
251 basal oxygen consumption rate (OCR). Each experiment was repeated at least in triplicates. The
252 investigator performing the seahorse experiments was blinded to the hypotheses at the time of
253 data analysis.

254

255 ***Serum injections***

256 Wild-type aged male C57/BL6 (21-23 months, NIA) were randomized into one of three
257 cohorts that received tail-vein injections of 100 μ L of young serum, 100 μ L of young serum
258 depleted of EVs, or sham injections. For studies of muscle function, animals were injected every
259 three days for a total of eight injections. Animals were injured with 10 μ L of 1 mg/mL of
260 cardiotoxin on Day 12 of the experimental paradigm and muscle function was evaluated on Day
261 23. For cognition studies, animals received a total of ten injections, and cognitive tests were
262 administered at the end of the ninth and tenth injection.

263 We tested four serum samples randomly for platelet contamination using a hemoanalyzer
264 (Hemvet 950FS, University of Pittsburgh Vascular Medicine Institute) and observed minimal-to-
265 no presence of platelets in the samples (average of 5K/ μ L serum).

266

267

268 ***EV isolation using size exclusion chromatography (SEC)***

269 EVs were isolated using iZon qEVsingle 35 nm or 70 nm size-exclusion chromatography
270 columns (Product Code: SP6). Columns were first allowed to equilibrate to room temperature
271 prior to use. Blood serum samples were thawed at room temperature, and centrifuged at 1,500 g
272 for 10 minutes, to remove any remaining cellular debris. After equilibrating the column to room
273 temperature, the cap and stopper were removed, and the column was washed with 1 mL of PBS
274 (Sigma: P5368). After washing, 100 μ L of serum was added onto the top filter of the column.
275 The eluted volume was collected in small Eppendorf centrifuge tubes. The first five fractions
276 (200 μ L each) were collected in a 1.5 mL tube. These fractions contain minimal amount of EVs
277 and are considered to be void fractions according to manufacturer's guidelines. Majority of the
278 EVs were eluted in fractions 6-11 (200 μ L each). These fractions, a total of 1.2 mL, were
279 collected together in a 2 mL tube. After isolation, EVs were stored at 4°C for up to one week.
280 Any unused EVs were then frozen and stored at -20°C for future use.

281 EVs were characterized for different surface markers (CD63 and CD81) using imaging flow
282 cytometry (Fig. 3), surface plasmon resonance imaging (Fig. 5), and in-well
283 immunofluorescence westerns (Supplemental Fig. 4).

284

285 ***Nanoparticle Tracking Analysis of EVs***

286 Nanoparticle Tracking Analysis (NTA) was performed using an NS300 NanoSight device
287 (Malvern Panalytical). Ten microliters from each EV sample was diluted 1:100 in type 1 EV-free
288 water and infused through the flow-cell using a syringe pump (Harvard Apparatus 98-4730).
289 Three 45-second videos were recorded for each sample, with the camera level set to 14. These
290 videos were batch analyzed by the software (NTA 3.3) with the detection threshold set to 3. The
291 flow-cell was washed with 1 mL of type 1 water between each sample.

292

293 ***Repletion of EVs in EV-depleted serum***

294 EVs were depleted from 100 μ L young serum as described above. From the same mouse,
295 another aliquot of 100 μ L young serum, EVs were isolated using size-exclusion chromatography,
296 as described above. The eluted EVs that were collected in 1.2 mL solution were subjected to
297 concentrating columns to concentrate the particles into a volume of 50 μ L (Product number:
298 UFC801008D, Millipore Sigma). The eluted samples were added to the 15 mL column and

299 centrifuged at 7,500 g for 10-20 minutes until the desired volume was attained. The concentrated
300 EVs were then added to the EV-depleted serum for downstream *in vitro* and *in vivo* studies.

301 To deplete EVs from 100 μ L serum, 25.2 μ L of Exoquick solution was added and the
302 mixture was placed on ice for 30 minutes in a 1.5 mL Eppendorf tube. Next, the mixture was
303 centrifuged at 1500 g for 30 minutes at 4C. The EVs were precipitated at the bottom, and the
304 supernatant was placed into another 1.5 mL Eppendorf tube. Another 100 μ L aliquot from the
305 same lot of serum was used to isolate EVs using size-exclusion chromatography. 100 μ L serum
306 yielded $\sim 2 \times 10^{10}$ EVs/mL in 1.2 mL eluted PBS solution. These EVs were then concentrated
307 into 50 μ L solution using the method described above. This volume was then added to the 100
308 μ L EV-depleted serum. Cells were treated cultured in 10% EV-depleted serum or EV-restored
309 serum conditions.

310

311 ***EV tracking in vivo***

312 EVs were depleted from 100 μ L young serum as described above. From the same batch and
313 another aliquot of 100 μ L young serum, EVs were isolated using size-exclusion chromatography,
314 as described above. The eluted EVs were then stained with 1 μ L PKH26 dye (P9691, Sigma) and
315 2 μ L of near-IR dye (EXOGV900A-1, System Biosciences) for one hour. EVs were then
316 concentrated to 50 μ L using the concentrating columns, as described above. The dyed EVs were
317 then added to the EV-depleted serum, which was injected via tail vein three days after
318 administering a cardiotoxin injury to one of the TAs of aged mice (contralateral TA uninjured).
319 The mice were euthanized 48 hours after the injection. TAs were isolated and imaged on the
320 LiCOR Odyssey Clx system in the near-IR (800 nm) channel. TAs were subsequently harvested
321 and frozen in nitrogen-cooled 2-methylbutane for histological analysis by a blinded investigator.

322

323 ***EV injections***

324 To investigate whether young EVs have a beneficial effect on skeletal muscle regeneration of
325 aged male mice, animals were injected with $\sim 5 \times 10^8$ EVs intramuscularly to the TA muscle three
326 days after injury. Next, aged mice were injected with EVs from young *Klotho*^{+/+} and *Klotho*^{+/-}
327 mice. For this, the aged mice received two intramuscular injections of $\sim 7.5 \times 10^8$ EVs at three- and

328 five-days post-injury. EVs were pooled from isolations of at least four different mouse serum
329 samples.

330

331 ***Animal injury model***

332 Mice were first anesthetized with 2% isoflurane and then received bilateral injuries to the
333 tibialis anterior (TA) muscles via intramuscular injection of cardiotoxin (10 μ L of 1mg/mL
334 cardiotoxin per TA). Animals were provided with an ingestible medigel, Carprofen, for pain
335 management. Fourteen days following injury, the animals were subjected to an *in situ* contractile
336 testing protocol to evaluate the injured muscle's force producing capacity. Following the
337 contractile testing, blood was isolated from the mice using a cardiac puncture. The animals were
338 then euthanized, and TAs were harvested for histological analysis.

339 Animals displaying evidence of external injuries and/or tumor growths were not included in
340 the study. We have found that some animals exhibit very severe injuries following injection,
341 whereas other animals display almost no functional deficit, as determined by the hang-impulse
342 testing. Therefore, with the goal of increasing the homogeneity across groups, animals were
343 tested one day after cardiotoxin injection, and only those animals displaying a hang-impulse
344 score within 25-75th percentile of the mean (range: 0.40-0.74 fold-change 14 dpi score when
345 compared to 1 dpi score) were subsequently randomized to one of the experimental groups (a
346 total of 16 animals fell outside the range). We chose the 25-75th percentile as a conventional
347 range to exclude potential outliers that fall in the 1st or 4th quartiles of the data set.

348

349 ***In situ contractile testing***

350 Contractile testing was performed 14 days after injury using an *in situ* testing apparatus
351 (Model 809B, Aurora Scientific Inc, Canada), stimulator (Model 701C, Aurora Scientific Inc,
352 Canada), and force transducer (Aurora Scientific Inc, Canada). Briefly, the peroneal nerve of
353 anesthetized animals was isolated through a small incision lateral to the left knee. Mice were
354 then placed supine on a 37°C-heated platform and the foot being tested was positioned on the
355 footplate. The left hindlimb used for testing was stabilized with cloth tape on the knee and foot.
356 Muscles were stimulated through the peroneal nerve by an electrode inserted beneath the skin.
357 Muscle peak twitch, time to peak twitch, and half-relaxation time with the ankle positioned at
358 20° of plantarflexion (the position that we determined to result in the greatest force output) were

359 quantified. Stimulations at 10, 30, 50, 80, 100, 120, 150 Hz were elicited to obtain a force-
360 frequency curve, with a 2-minute rest between each contraction. Bilateral TA muscles were
361 subsequently harvested and frozen in nitrogen-cooled 2-methylbutane for histological analysis by
362 a blinded investigator.

363

364 *Immunofluorescence imaging*

365 Cell-seeded chamber slides were fixed with warm 2% Paraformaldehyde for 15 minutes, then
366 washed with phosphate-buffered-saline (PBS) three times. The samples were then permeabilized
367 with 0.1% Triton-X for 15 minutes after which the samples were blocked with 3% BSA and
368 0.1% Triton-X for 45 minutes. A similar process was followed for muscle cryo-sections up to the
369 point of the blocking step. After blocking, the samples were incubated overnight at 4°C with the
370 following primary antibodies in antibody solution (3% BSA+5% Goat Serum+0.1% Triton-X), at
371 the dilutions mentioned below:

372

Antibody	Host-species	Product number	Dilution
MyoD	Rabbit	SCBT, sc-760	1:500
MyoD	Mouse	sc-377460	1:500
Desmin	Rabbit	Abcam, ab15200	1:500
Klotho	Rat	R&D systems, MAB1819, Lot# KGN0315101	1:400
Laminin	Rabbit	Abcam, ab11575	1:500
Collagen I	Rabbit	Abcam, ab21286	1:500
SDHA	Mouse	Abcam, ab14715	1:500
Pax-7	Rabbit	Abcam, ab187339	1:100
Pax-7	Mouse	DSHB	5 µg/mL

373

374 After incubating the samples with primary antibodies overnight, samples were washed with
375 PBS three times, after which they were incubated with host-specific secondary antibodies in
376 antibody solution for one hour at room temperature at the dilutions mentioned in the table below:

377

Antibody	Host-species	Product number	Dilution
AlexaFluor 594	Rabbit	Life Technologies, A11012	1:500
AlexaFluor 488	Rat	Life Technologies, A11006	1:500
AlexaFluor 594	Rat	Life Technologies, A11007	1:500
AlexaFluor 488	Mouse IgG1	Life Technologies, A21121	1:500
AlexaFluor 594	Mouse IgG2b	Life Technologies, A21145	1:500
Phalloidin 647	N/A	Life Technologies, A22287	1:500

378

379 After a triple wash with PBS, the cells were incubated with their respective secondary
380 antibodies, goat-anti Rat Alexa Fluor 488 or 594, goat anti-Rabbit Alexa Fluor 546 and
381 Phalloidin 647 in 3% BSA+5% Goat Serum+0.1% Triton-X was diluted 1:500 for 60 minutes.
382 Following a triple wash with PBS, the chamber slides were stained with DAPI for 2 minutes and
383 then washed with PBS again. The chamber sides were mounted with a glass coverslip using
384 Gelvatol (Source: Center for Biologic Imaging (CBI), University of Pittsburgh) as a mounting
385 media. These were dried in 4°C for at least three hours before imaging. Imaging was performed
386 using 20X magnification on Zeiss-Axiovision microscope.

387 For Nonyl Acridine Orange (NAO) staining (Thermofisher, A1372), the fixed and
388 permeablized cells were stained with 5 μ M NAO made in HBSS (-Ca²⁺, -Mg²⁺), for 15 minutes.
389 The cells were then washed with PBS, following which the cells were stained with DAPI for two
390 minutes and washed with PBS again. The cells were mounted with a glass coverslip using
391 Gelvatol (Source: Center of Biologic Imaging, University of Pittsburgh). The slides were dried at
392 4°C and imaged using 20X magnification on Zeiss-Axiovision microscope using the FITC
393 channel to measure reduced cardiolipin.

394 Imaging analysis was done using ImageJ. For *in vitro* experiments, Klotho, NAO, and
395 SDHA were quantified as protein per cell. Pax7, MyoD, and Desmin were quantified as
396 percentage of cells positive for those markers divided by total number of cells within an image.
397 For *in vivo* experiments, SDHA was quantified as a function of protein level in every centrally
398 nucleated (regenerating) fiber. For this, the myofibers were manually traced and integrated
399 density of SDHA was computed for each of the traced myofiber as the output. A total of SDHA
400 expression in all regenerating myofibers were quantified as output for each image. Collagen I

401 was quantified as total protein per unit area of image taken. Area of regenerating myofibers were
402 quantified by manually tracing the laminin in the myofibers.

403

404 ***RNA-seq analysis***

405 TA muscles from the three groups of aged animals (young serum injections, depleted young
406 serum, or saline injections) were collected for RNA sequencing on day 23 to Novogene
407 Corporation, Inc. Quality control of all RNA samples was performed on an Agilent 2100
408 Bioanalyzer instrument and samples with RIN > 5.5 and total RNA yield > 400 ng were further used
409 for library construction. Only those samples that passed the quality check requirements for library
410 preparation with poly A enrichment were utilized in this study (3 animals from sham, 4 animals
411 from young serum, and 4 animals from young serum depleted of EVs groups). Libraries were
412 sequenced on NovaSeq 6000 with PE150 strategy. Poor quality reads were eliminated with the
413 criteria for Phred score Q30 >80%. Reads with adaptor contamination and uncertain nucleotides
414 (N) with > 10% content was removed. PartekFlow STAR - 2.7.3a was used to align reads to
415 mm10 genome. Uniquely aligned reads were used for downstream analysis.

416 Principal component analysis (PCA) performed in R revealed the distinction between groups.
417 Linear discriminant analysis (LDA) was done with first 6 PCs was used to reduce dimensionality
418 and visualize clearly separate clusters. Further DeSeq2 was performed with FDR<0.1. The Venn
419 diagram (Fig 3b) shows global differentially expressed (DE) genes with log fold change (LFC)
420 magnitude > 0.1. Gene Ontology (GO) enrichment analysis was performed using Enrichr
421 (Maa'yan lab) with cut-offs of FDR < 0.1, LFC > 1.5. First, genes with LFC magnitude greater
422 than 1.5 was performed. The GO terms were ranked based on combined score ranking.

423

424 ***Human serum collection***

425 Human serum was purchased from a commercially available vendor, Innovative
426 Research. Blood was collected from young males (18-35 years) and aged males (65-80 years)
427 and serum was collected off-the-clot. No collection was performed at the University of
428 Pittsburgh.

429

430

431


432 ***Probing CD63, CD81 and Klotho mRNA in circulating EVs for ImageStream analysis***

433 PrimeFlow™ was performed according to the manufacturer's instructions. Two standard
434 20bDNAs Mouse Klotho oligos probe sets VB1-6001084 (Part No. 6003837) and VB10-
435 6001085 (Part No. 6003838) tagged with Type 1 Alexafluor AF647 and Type 10 Alexafluor
436 AF568 dyes, respectively were utilized. Expression of total mRNA was reported based on the
437 sum of fluorescence intensities of type 1 and type 10, at the single EV resolution. The Type 1
438 probe was designed to hybridize to region 2803-3753 of the full canonical Klotho sequence. The
439 Type 10 probe was designed to hybridize to region 2585-3597 of the full Klotho_202 sequence.
440 To probe for human Klotho mRNA, probe set VA1-3005823-PF tagged with Type 1 Alexafluor
441 AF647 was utilized. Expression of total mRNA was reported based on total intensity of Klotho
442 mRNA per EV. The sequences targeted by the probe are listed below.

443 Circulating EVs from four young animals and four aged animals were pooled together to
444 form one sample each of the young and aged groups. The EVs were then fixed with equal parts
445 of RNA Fixation Buffer 1A and 1B for 30 minutes at 4°C. The EVs were then centrifuged at
446 16,100 g at 4°C for 30 minutes and the supernatant was discarded. EVs were incubated with
447 CD63 (Santa Cruz, sc-5275) and CD81 (Santa Cruz, sc-7637) in RNA permeabilization buffer
448 with 1X RNase Inhibitors, at 4°C in the dark for two hours. The target probes (VB1-6001084
449 (Part No. 6003837) and VB10-6001085 (Part No. 6003838)) were then thawed to room
450 temperature. In the meantime, the EV suspensions were washed with RNA wash buffer and
451 centrifuged at 16,100 g at 4°C for 30 minutes. Target probes were diluted 1:20 in target probe
452 diluent and 100 µL of the diluted probes were added to each EV suspension. These were
453 incubated for two hours in a dry oven at 40°C. After the incubation period, wash the samples
454 with RNA wash buffer with 1X RNase inhibitors and centrifuge at 16,100 g for 30 minutes at
455 room temperature. The supernatant was removed till the 100 µL level, re-suspended in the
456 residual volume and stored in the dark at 4°C, overnight.

457 The next day, the EV samples were brought to room temperature and 100 µL of pre-amp
458 mix was added to each sample. These samples were incubated at 40°C for 1.5 hours. After
459 washing with RNA wash buffer, the samples were centrifuged at 16,100 g for 30 minutes at
460 room temperature. During this time, the probe labels were thawed on ice. Next, 100 µL of amp-
461 mix was added to each sample and incubated at 40°C for 1.5 hours. Next, the samples were
462 mixed with wash buffer, centrifuged at 16,100 g for 30 minutes at room temperature. The

463 supernatant was removed until the 100 μ L mark and the residual volume was re-suspended. The
 464 thawed probe labels were diluted 1:100 in label probe diluent and 100 μ L of this was added to
 465 each of the EV sample. The samples were incubated at 40°C for one hour. The samples were then
 466 mixed with wash buffer and centrifuged at 16,100 g for 30 minutes at room temperature. The
 467 supernatant was removed, and the residual volume was stored in IC fixation buffer provided in
 468 the kit, overnight at 4°C. Prior to taking the samples to flow imaging, the samples received 1 μ L
 469 of PKH26 for 10 minutes. The samples were washed in wash buffer and centrifuged at 16,100 g
 470 for 30 minutes at 4°C. The supernatant was removed until the 100 μ L mark and the residual
 471 volume was mixed gently. These samples were imaged on Imagestreamx MarkII system at the
 472 flow cytometry core of the Department of Immunology at the University of Pittsburgh. The EVs
 473 were gated for size and positive signal of PKH26 (see below for gating strategy). Three
 474 independent runs were done for staining and imaging of EVs.



475
 476 **Representative gating strategy for acquisition of EVs on ImageStream instrument.** A gating strategy
 477 to include nanoparticles with (A) high circularity and small area (R1), and (B) positive PKH26 signal
 478 (R2) was used to image the young and aged serum EVs.
 479

480 Information on the probes designed to target Klotho transcripts in circulating EVs are as follows:

481 **1. Type 1 probe (mouse Klotho):**

482 Accession: NM_013823.2

483 Region covered by Probe-set: 2803 – 3753 (951bp) (red region)

484 GATAATCATTGCTCGTGGGGCGGCGGGAGCGGGGGTGGGCACCGCGTAGGGAGGGCGGCGGGGCGCG
485 GGCATATAGGGGCGCGGCGCGGTGCCCTCCGGCTCCCGCAGCATGCTAGCCCCGCGCCCTCCTCGCC
486 GCCCCGCCGCGGCTGGTGTGCTCCGTTTGTGTTGCTGCATCTGCTGCTGCTCGCCCTGCGCGCCCGCT
487 GCCTGAGCGCTGAGCCGGGTACAGGGCGCGCAGACCTGGGCTCGTTTCGCGCGCGCTCCTGCCCCAGAG
488 GCCGCTGGCCTCCTCCACGACACCTTCCCCGACGGTTTCTCTGGGCGGTAGGCAGCGCCGCCTATCAG
489 ACCGAGGGCGGCTGGCGACAGCACGGCAAAGGCGCGTCCATCTGGGACACTTTCACCCATCACTCTGG
490 GGCGGCCCCGTCGACTCCCCGATCGTCGTGGCGCCGTCGGGTGCCCGTCGCCTCCCCTGTCTCCAC
491 TGGAGATGTGGCCAGCGATAGTTACAACAACGTCTACCGCGACACAGAGGGGCTGCGCGAACTGGGG
492 GTCACCCACTACCGCTTCTCCATATCGTGGGCGCGGGTGTCTCCCAATGGCACCGCGGGCACTCCCAA
493 CCGCGAGGGGCTGCGCTACTACCGCGGGTGTCTGGAGCGGCTGCGGGAGCTGGGCGTGCAGCCGGTG
494 GTTACCCTGTACCATTGGGACCTGCCACAGCGCTGCAGGACACCTATGGCGGATGGGCCAATCGCGC
495 CCTGGCCGACCATTTACAGGATTATGCCGAGCTCTGCTTCCGCCACTTCGGTGGTCAGGTCAAGTACTG
496 GATCACCATTGACAACCCCTACGTGGTGGCCTGGCACGGGTATGCCACCGGGCGCCTGGCCCCGGGCG
497 TGAGGGGCAGCTCCAGGCTCGGGTACCTGGTTGCCACAACCTACTTTTGGCTCATGCCAAAGTCTGG
498 CATCTTACAACACCTCTTCCGCCCCACACAGGGAGGGCCGGGTGTCTATCGCCTTAAGCTCCCATTGG
499 ATCAATCCTCGAAGAATGACTGACTATAATATCAGAGAATGCCAGAAGTCTCTTGACTTTGTGCTAGG
500 CTGGTTTGCCAAACCCATATTTATTGATGGCGACTACCCAGAGAGTATGAAGAACAACCTCTCGTCTCT
501 TCTGCCTGATTTTACTGAATCTGAGAAGAGGGTTCATCAGAGGAACTGCTGACTTTTTTGTCTCTCCTT
502 CGGACCAACCTTGAGCTTTCAGCTATTGGACCCTAACATGAAGTTCGCCAATTGGAGTCTCCCAACCT
503 GAGGCAGCTTCTGTCTTGGATAGATCTGGAATATAACCACCCTCCAATATTTATTGTGGAAAATGGCTG
504 GTTTGTCTCGGGAACCACCAAAAGGGATGATGCCAAATATATGTATTATCTCAAGAAGTTCATAATGG
505 AAACCTTAAAAGCAATCAGACTGGATGGGGTCGACGTCATTGGGTACACCGCGTGGTCGCTCATGGAC
506 GGTTTCGAGTGGCATAGGGGGCTACAGCATCCGGCGAGGACTCTTCTACGTTGACTTCTGAGTCAGGA
507 CAAGGAGCTGTTGCCAAAGTCTTCGGCCTTGTCTACCAAAGCTGATAGAGGACAATGGCTTTCCTC
508 CTTTACCTGAAAACCAGCCCCTTGAAGGGACATTTCCCTGTGACTTTGCTTGGGGAGTTGTTGACAAC
509 ACGTTCAAGTGGACTACTCTCTCTCAGTTTACTGACCCGAATGTCTATCTGTGGGATGTGCATCACA
510 GTAAGAGGCTTATTAAGTAGACGGGGTTGTAGCCAAGAAGAGAAAACCTTACTGTGTTGATTTCTCT
511 GCCATCCGGCCTCAGATAACCTTACTTCGAGAAATGCGGGTACCCACTTTCGCTTCTCCCTGGACTGG
512 GCCCTGATCTTGCCTCTGGGTAACCAGACCCAAGTGAACCACACGGTCTGCACCTTCTACCGCTGCATG
513 ATCAGCGAGCTGGTGCACGCCAACATCACTCCAGTGGTGGCCCTGTGGCAGCCAGCAGCCCCGCACCA
514 AGGCCTGCCACATGCCCTTGCAAAACATGGGGCCTGGGAGAACCCGCACACTGCTCTGGCGTTTGCAG
515 ACTACGCAAACCTGTGTTTTAAAGAGTTGGGTCACTGGGTCAATCTCTGGATCACCATGAACGAGCCA
516 AACACACGGAACATGACCTATCGTGCCGGGCACCACCTCCTGAGAGCCCATGCCTTGGCTTGGCATCT
517 GTACGATGACAAGTTTTAGGGCGGCTCAGAAAGGCAAAATATCCATCGCCTTGCAGGCTGACTGGATAG
518 AACCAGCCTGCCCTTCTCTCAAAATGACAAAGAAGTGGCCGAGAGAGTTTTGGAATTTGATATAGGC
519 TGGCTGGCAGAGCCTATTTTTGGTTCCGGAGATTATCCACGTGTGATGAGGGACTGGCTGAACCAAAA
520 AAACAATTTTCTTTTGCCTATTTACCCGAAGATGAAAAAAAGCTAGTCCGGGGTTCTTTGACTTCT
521 GGCGGTGAGTCATTACACCACCTTCTGGTAGACTGGGAAAAGGAGGATCCGATGAAATACAACGAT
522 TACTTGGAGGTACAGGAGATGACTGACATCACATGGCTCAACTCTCCAGTCAGGTGGCAGTGGTGGC
523 TTGGGGGCTGCGCAAAGTGTCAACTGGCTAAGGTTCAAGTACGGAGACCTCCCAGTGTATGTGACAG
524 CCAATGGAATCGATGATGACCCCCACCCGAGCAAGACTCACTGAGGATCTATTATATTAAGAATTAT
525 GTGAATGAGGCTCTGAAAGCCTACGTGTTGGACGACATCAACCTTTGTGGCTACTTTGCGTATTCACTT
526 AGTGATCGCTCAGCTCCCAAGTCTGGCTTTTATCGATATGCTGCGAATCAGTTTGAGCCCAAACCATCT
527 ATGAAACATTACAGGAAAATTATTGACAGCAATGGCTTCTGGGTTCTGGAACACTGGGAAGGTTTTG
528 TCCAGAAGAATACACTGTGTGCACCGAATGTGGATTTTTTCAAACCCGGAAGTCTTTGCTGGTCTTCAT
529 CTCGTTTCTGTTTTTACTTTTATTATTCTCTTGTCTCATTTTTTCACTACTCCAAGAAAGGCCAGAGA
530 AGTTATAAGTAATGTGAACGTCTGCCTGGCCATTCGCTTTGGGATCAAGATGTACACGCCGTACGCCG
531 TTTGCACCTCTCTGTGTTGTGAGCCGATTCCACACATTTGATTCTAGAAAACCTTTTTGTGATGGGT
532 GGTAGAGGTTTTAAACAGGAATTGGTGAGAATAAAATATTGCAGGGTGAATGGTATCTGAATCTGCTC
533 TCTTTGGTGGCAATTACCGAATTATACTCACCACAGTTTCTACAGTGCCCCGGAATGGAAGGCATAGA
534 ATACGGTAGGGATAACAGTGCCAAGCAGACAGAAGTTTTAAAGAACAACCTTTAGGGACTTGTATCCA
535 TGCCATTTTTAAATCACTCCTGTTGGGGAGTAACACTCTCTCAATTACCATCTTAACACCTGGACTTT

536 ACCTGATCCAGTTTTACAAGGTGAAGTAGAAAAATATCCAGTAAAGGTGGCCAAGAGCCCTGAGTCCA
537 GAGCAGCCCATTAAAGAAGCACTATTCCTACCAAATGCTGCTAATGTCAATTTACAAATATACTTAGAA
538 AGCACATTATGGACATTTGTATTCTTGTGAATGTTTTTGGAGGTGTGCCCTAAACCCAGATCCTTGAGG
539 GCTTTCTCTTACCAACTTTCCTTTCAGAGCCTGCTTGTGGAGATTCTTCCCCAGCCCCCTTCCCCTTTC
540 CCTCTTGCTCTGCCCCACCTCGCTCCACCCAGCTTGCTCCAGCCCAAAGATTCTTTATTTGTTTCTCATT
541 ACCGAAGGTTGTGAGCCACCATGTGGTTTCTGGGATTTGAACTCATGACCTCCGGAGGAGCTGTCATG
542 CTCTTAACCAGCCCATGTTGAAGATTCTTTTGATAAATATTCACAAAAAATAAAGATGAGCCATGAGC
543 TGTTGGCCTCTTCGGAAGCGGAAACTGAGTGATTGATTGAACATCCTTTTATCTTTGACCAGACCTTG
544 GAATGAATGCAATGACCTTTCACAGGAAGAAGGAGGAGCTCTCAGTCAAACCTGTAAAGAATGCCT
545 CTTCAGAATATGCTGTCAGTGCTTGGATGCCATGATGTTCAACTTCTTAGTCGATCCGGCAGCAATCA
546 CAGTGTGAGCACACTGGGAACCTGTCCTTTCGGCCCGGAGATCTACCGTGTGCTTCTGTGAAGAGGC
547 TTTGACGTAGCCCCTCTTTGAGCTCTTACACCATGCTACTGACTTCTAGAAAGGCTAATTAGGTCTTCTT
548 CTACACCTAATACCCTAAGTCTTACTGACTCTCACGGGAGAAGTCTCTGTGCTACACCTGAGTGGTCTT
549 ATTGATAACCCTGATACCAGATCAGGCAAGATAAATCCGTCATAGCAGGCATGGCTACCCTTGCTGCC
550 ACAGGGTCACAGCACATAGCTCATCACCTGTTATTCTTCATCTTGCAATGTGGTATGGTTTTCTGGT
551 GAATGATCAGCTTTTTGCTGTGGTATTCTTTATACATCTGGACTTATTATTGAAATCAAATGCTATAGAA
552 TCAATAGTTTATTTTATGTCTATTTTTCTTGATCGCAGAGTAATATATATTAATTGTAAAAAATTTAAGA
553 AACAAAACTATATGTAAAGAAAAAATTATAATATAATACAGAGATGCTGCTGACAGTTCCCTATGTGT
554 TGTGTTTTGTATACTGAGATCATGTGATACGTAGGCATACATCTTCTTGGGTTTTTTTTGTTTTTTTT
555 GTTTTGTTTTGTTTTGTTTTGGTTTTTTGAGATAGGGTTTCTCTGTATAGCCCTGGCTGTCCTGGAATC
556 ACTTTGCAGACCAGGCTAGCCTCAAACCTTATTTCATTTTTACTGAAGTAATTTTTCTGTCATTAGTCTT
557 CAAGAGCAAACCTTTAATAGTTATGGAGAATATTGCCAGAACAGCTCAAACCTGTTTTATTTGTTGGT
558 CCAATTTCCCATTAATTAGTTCAATAATAAATATCATTTAGAAATAAAAAAA

559

560 **2. Type 10 probe (mouse Klotho):**

561 Accession:ENSMUST00000202096.1 K1-202

562 Region covered by probe-set: 2585 – 3597 (1013bp) (red region)

563 **eggctcccgcagcatgctagccccgcgccctcctcgcgcccccggctggtgctgctccgttgctggtgctgcatctgctgctgctgcccctgcgcgcccgctgc**
564 **ctgagcgcctgagccgggtcaggcgcgcagacctgggctcgttcgcgcgcctcctgccccagagcccctggcctcctccacgacacctccccgacggttctc**
565 **ctgggcggtaggcagcgcgcctatcagaccgaggcggctggcgacagcacggcaaggcgcgtccatctgggacacttcacccatcactctggggcggcccc**
566 **gtccgactccccgatcgtcgtggcgcctcgggtgccccgtcgcctcccctgtcctccactggagatgtggccagcgcgatgttacaacaacgctaccgcgacacagag**
567 **gggctgcgcgaactgggggtcaccactaccgcttctccatctcgtgggcgcgggtgctccccaatggcaccgcgggactcccaaccgcgaggggctgcgctacta**
568 **ccggcggctcgtgagcggctcgggagctgggcgtgcagccgggtgttacctgtaccattgggacctgccacagcgcctgcaggacacctatggcggatggcc**
569 **aatcgcgcctggccgaccattcagggattatgccgagctcgttccgccacttcggtggtcaggtcaagfactggatcaccattgacaaccctacgtggtggcctgg**
570 **cacgggtatgccaccggcgcctggccccggcgtgaggggacgtccaggctcgggtacgtggtgcccacaacctacttttgctcatgccaagtctggcatctct**
571 **acaacctctttccgccccacacaggaggccgggtgtctatcgccttaagctcccattggatcaatcctcgaagaatgactgactataatatcagagaatgccagaagt**
572 **ctcttgactttgctagctggtttgccaaccataattatgatggcactaccagagagtatgaagaacaacctctcgtctcttctgctgatttactgaactgagaag**
573 **aggctcatcagaggaactgctgactttttgctctccttcggaccaaccttgagctttcagctattggaccctaacatgaagtccgcaattggagtcccaacctgagg**
574 **cagcttctgcttgatagatctggaatataaccacctccaataattatgtgaaaatggctggtttgctcgggaaccacccaaaaggatgatgccaatafatgtattatc**
575 **tcaagaagtataatggaaacctaaagcaatcagactggatgggctgacgtcattgggtacaccgcgtgctcgtcatggacggtttcgagtggcataggggctac**
576 **agcatccggcgaggactctctactgtgactttctgagtcaggacaaggagctgtgccaaaagctctcggcctgttctaccaaaaagctgatagaggacaatggcttctcc**
577 **ttfacctgaaaaccagccccgtgaaggacatttccctgtgactttctggtgggagttgtgacaactacgttcaagt**aaagtccttgacaaaaccagtgctgcgctctgctt
578 cctcactaagctctgccaaggcacagtgtgggacgttgagccaaacagggttccctagtgacttatgaactacatagctctgaacgctcagcttcaaacatcttcaa
579 tctacatctgtgctctccattaggtccaagggaacagattcaaacatgaatatgtaagctctgtaagacaatacaagataaggcacttcccttgggtgtacgctgg
580 ggtccctgctcaggaagtaagttttcataataagattcaacacagaagtcggagcatctcagggaagtgctgagaatgctgagcatttagcagatttctcctcact
581 gtaaatgccccactccaggtcatagaaaaaaatctcaaaaagcaaacattgattcaatgatttattgatagcaccaaggcattccaaaatgatcagttagtattactg

582 agcatcaaaactgtgtaggaagtccctcaaaaccattttatTTTTtagttccccagtgttaaagtgactgtttcttgggttgaccaatactttatgtaagcacttgctgactgcc
583 agttgtgtatgaaacccccatgggggtgctgggtccctttgtgaggaagaccaaaagttcagtatctgtagtcagatctcaaggtttagcatggtggagctggctcagtggt
584 ctcaacctctaatgccaccgccctttaacgggtcctcatgtttagtgacaccaaaaccatgatattttttggtctacctataatgfaagttggcacggctatgtattg
585 taatgtaaatatctgtttttctgatggcttaagcaatctgtgaaagggtttgacctcaaaaggccgtgaccacaggtgagaactactgtttagtccagaaggag
586 gggtcacaagtgtgacttcaaaagaataattcggaaaaatgcttaggtccaaggggagcttcttattggaatggaattttggtctctgtagatagcaaatgctttgtttgt
587 ttgaagtacatcgctatcctgatgtatttgcctctgtgatgtaagatgctctttggctcttagactatgtagctcaatctagaggtgattttggacttaagtctctcttac
588 ctcaaaagacagctgagcaatgttgagtgagctctattgaggcctgggatggcaccatagggtctcatggtgtgtttccagcttgggtctattgacagctagttgaaca
589 gtgggggtgctgggtctactggaagaggtctttagatcacaagggtcatgtctaaagagagtagtgggacctcaaccctttctctcttttctctattttatcatgaaa
590 caagcagtttgcatactctgtgccccgactctgggtgtccaacttaccacagctccccaaacagtggagccattgattgttccgggacatccaaagtcatgagccca
591 aatcagccttggtctctgatttctcaggtttgctagaactgacaggatgttagccaatcagtaacatcagcaccatcctgctcagtggtgaggtattttctgctccatctccc
592 acttctctcagaacaaggctatctgattgtcctatcctaattcgtcagatctacagtgaaagtttaggttagctctaatgtggcagaatggagatgcaaggagggag
593 aagaagataatgtgtccacatccccctcttacctttttggggccaggagtagattagatagctctggtcttgttatttcttaccttggaggttctctgctggcc
594 acatcctgactggaggtcacacacattgtctgcatagcagctggagctgccaagtactctgttacagtcagctactcagactgcactctgtacagcgagacagg
595 gctgtgtgggaaggccattctctcccacctgtcctcctaaaggtattgtgtcttcacagcgtgaaagtcaggggtttgtctgatgttcttgaagagaagggaaccc
596 caatcagaatcaaatcatggcagtgataggaatgtgaggggtggggaggagaagcttgtttgtttttgattttgtatctctcattttgcaggacctgtacctgctag
597 tcaactgtactgagtcacacatcaactcctaaggctgtgtcaggatctcaccagacatcagcagatgcaatggccccagctcctctctgtctacattgttgatcatctac
598 tcagggtgtctgactgctacatgttcaaggccctctgcatctctgtgalcccaacccaaateccaaaatccatattcaacctgtgtgtgtaaacgctctggaagct
599 cccgggtgggaacaggctatagttagggttactctgctgctgctgctgctgcttctcttaggtcatcagactcctctcaagacaacccccggctgacagcatcag
600 aacgcctaattgttctctcagtgtagctgggtgtctttgtgacaagcagggtcagcacgtctacaacattatgttacgttagtctcaagaagtgatttttttaacgaat
601 ttgtattagtcttgggggattctatagtgaaattgggtcatatttacttctcttattatccccctaactcttccagatccattcacatcttccaaacccccaaactcacattgtc
602 ccacctctcatatggacatttactgtgattgtattgcccagcaactcctgtgggggaccatcctctggaattgtgccacctacgaagacctacatcctaaaggaaaatt
603 cactctcctgccctaaaagccattatcttgagcaggtgctcaagaacctattttcttctctcccttttcttctcttctctctctctctctctctctctctctctct
604 ctttcttctctctctctctctcttcttcttcttcttcttcttctctcttc
605 cccttctctctctctctctttatgttcatgctgactggcttctctgttagacaaccccagatgctgtgagttcatgagtacagaggttctatctctgtactcccaacc
606 tctgctgacaacctctctctcttagatggctcctgagttgtgagttctatgaaccactgtcactgcaccaagaaacttaagaagtgatttaaaaaaaaaaaacctaa
607 agtttcttcttctctctctggttagtctcactcaagagttgggtcatatatttccccaataaataaaaaatccccctagccaggtgatgggtggtcacaccttagtcc
608 cagcactcaggaggcagagggcaggtggtatctgtgagtttgagggccgctgctgcagagtgagttcaagacagccagggctacacagagaacctgtcttgaa
609 aaacaaaaacaaaacaaacaaatgtatgtgtgtgtaggggtgatgatgatgtgtatgatactgtgtgtgtgtgtgtgtgtgtatctcctagctacacaccacc
610 tgttagaagttgtagctgggcacatccacatgggggagggggtcactttgtcacaaccagtgtcccagctcctgagttgcttctcatgctactggtgtgttagtgacc
611 aaaatgaagcaggttacatacaacatagacatcatgtgtgctactgctgtgagagagactttatcaataaacaattgaatatatgtttgtctcaacctcctcagacct
612 attttacttttagtaaacctaaggcagcaagctgctataataaagttagaggaactttgctgcacactcattctacattttcttagttggagaactgacctaccatctg
613 caactttacatggtcttctactgtttagtagtagactcaatagaaactgtattctgggatggttctgtagagaagttgtgaatttagtacattcagagttgaataaaaaata
614 cc

615

616 3. Type 1 probe (human Klotho):

617 Accession: NM_004795.3

618 cgcgcagcat gcccgcagc gccccgcgc gccgcccgc gccgcgccg ccgtcgtctg
619 cgctgctgct ggtgctgct ggctggggc gccgcccct gcgtgcggag ccgggcgacg
620 gcgcgcagac ctgggcccgt ttctcgggc ctctgcccc cgaggccgc ggctcttcc
621 agggcacct ccccgacggc ttctctggg ccgtggggc cgcgcctac cagaccgag
622 gcggctggca gcagcagggc aagggtgcgt ccatctggga tacgttcacc caccacccc
623 tggcacccc gggagactcc cggaaccca gtctgccgtt gggcgcgccg tcgccgtgc
624 agccccac cggggacgta gccagcgaca gctacaaca cgtctccc gcacagggag
625 cgtgcgcga gctcggggc actcactacc gcttccat ctctggggc cgagtgcctc
626 ccaatggcag cgcgggcgct cccaaccgc aggggctgc ctactaccg gcctctctg
627 agcggctgc ggagctggc gtgcagccc tggcaccct gtaccactgg gacctgccc
628 agcgctgca gtcagcctac ggcggtggg ccaaccgc cctggccgac cactcaggg
629 attacgga gctctgctc cgcacttcg gcggtcaggt caagtactg atcaccatg
630 acaacccta cgtggtggc tggcacgct acgccaccg gcgctggcc cccgcatcc

631 ggggcagccc gcggtcggg tacctggtgg cgcacaacct cctcctggct catgccaag
632 tctgcatct ctacaact tcttccgtc cactcaggg aggtcaggtg tccattgcc
633 taagctctca ctggatcaat cctcgaagaa tgaccgacca cagcatcaaa gaatgcaaa
634 aatctctgga cttgtacta ggttggttg ccaaacctgt atftattgat ggtgactatc
635 ccgagagcat gaagaataac ctttcatcta ttctgcctga tttactgaa tctgagaaaa
636 agttcatcaa aggaactgct gactttttg ctctttgctt tggaccacc ttgagtttc
637 aacttttggg cctcaccatg aagttccgcc aattggaatc tccaacctg aggcaactgc
638 tttcctggat tgacctgaa ttaaccatc ctcaaatatt tatttggaa aatggctggt
639 ttgtctcagg gaccaccaag agagatgatg ccaaatatat gtattacctc aaaaagtca
640 tcatggaaac cttaaagcc atcaagctgg atggggtgga tgcacatggg tataccgeat
641 ggtccctcat gtaggttgc gtagtggcaca gaggttacag catcaggcgt ggactctct
642 atgtgactt tctaagccag gacaagatgt tgtgcaaaa gtcttcagcc ttgttctacc
643 aaaagctgat agagaaaaat ggcttccctc ctttacctga aatcagccc ctagaagggg
644 catttccctg tgactttgct tggggagtg ttgacaacta cattcaagta gataccactc
645 tgtctcagtt taccgacctg aatgtttacc tgtgggatgt ccaccacagt aaaaggctta
646 ttaaagtgga tggggtgtg accaagaaga gaaatccta ctgtgtgac ttgtgcca
647 tccagccca gatcgttta ctccagaaa tgcacgttac acatttccgc ttctccctgg
648 actggccct gatttccct ctgggtaacc agtccaggt gaaccacacc atctgcagt
649 actatcctg catgctcagc gagcttgcg gtgtcaacat caccacagt gtggcctgt
650 ggagcctat ggccccgaac caaggactgc cgcgcctct gccaggcag ggcgcctggg
651 agaaccctca cactgcctg gcctttgcag agtatgccc actgtgctt caagagctg
652 gccatcacgt caagcttgg ataacatga atgagccgta tacaaggaat atgacataca
653 gtgctggcca caacctctg aaggccatg cctggctg gcatgtgtac aatgaaaat
654 ttaggcatgc tcagaatggg aaaatatcca tagccttga ggctgattg atagaacctg
655 cctgcccctt ctccccaaag gacaagagg tggctgagag agttttgaa ttgacattg
656 gctggctggc tgagccatt ttcggctctg gagattatcc atgggtgatg agggactggc
657 tgaaccaaag aaacaattt ctcttctt atttactga agatgaaaa aagctaacc
658 aggttacct tgacttttg gctttagcc attataccac catcttga gactcagaaa
659 aagaagatcc aataaaatac aatgattacc tagaagtca agaataacc gacatcacgt
660 ggctcaactc cccagtcag tggcggtg tgcctgggg gttgcgcaa gtgctgaact
661 ggctgaagt caagtacgga gacctccca tgtacataat atccaatgga atcgatgacg
662 ggctgcatgc tgaggacgac cagctgaggg tgtattat gcagaattac ataaacgaag
663 ctctcaaaag ccacatactg gatggtatca atctttgagg atacttctg tattcttga
664 acgaccgcac agctccgagg ttggcctct atcgttatgc tgcagatcag ttgagccca
665 aggcacatc gaacattac aggaaaata ttgacagcaa tggttcccg ggccccgaaa
666 ctctgaaag atttgtcca gaagaattca ccgtgtgtac tgagtgcagt tttttcaca
667 cccgaaagtc ttactggtc tcatagctt tctatttt tcttctatt atttctct
668 ccttataat ttactactg aagaaaggca gaagaagta caaatagtc tgaacattt
669 tctattcatt catttgaaa taattatgca gacacatcag ctgttaacca ttgcacctc
670 taagtgtgt gaaactgaa atttacata ttgacttct agaaaacatt ttgtggctt
671 atgacagagg tttgaaatg ggcatagggt atcgtaaaat atgaaataat gcgaatagt
672 cctgaattg ttcttttt gggtgattaa aaaactgaca ggcactataa ttctgtaac
673 acactaacia aagcatgaaa aataggaacc acaccaatgc aacatttgc cagaaattg
674 aatgacaaga ttaggaatat ttcttctgc acccactct aaatttaag ttttctgga
675 agtagtaatt gcaagagtc gaatagaag ttatgtacca agtaaccatt tctcagctgc
676 cataataatg cctagtggct tcccctctg caaatctagt ttctatgga aaagaagatg
677 gcagatacag gagagacgac agagggtcct aggtcggat gttccttctg aaagcaatg
678 ttctatcaaa tactagtatt aatttatgta tctggttaac gacatactg gagagcaat
679 tatgaaatg tttatttat atgattttg aggtcctgtc taaacctgt gtcctgagg
680 gatctgtctc actggcatct tttgagggc ctgacataa ggaaactttt gataagtac
681 tgcggaaaaa caaacatgaa tctgtgata ttggctctt caggaagcat aaagcaattg
682 tgaatacag tataccgag tggctctagg tggaggaaa gaggaaaaag tcttattat
683 gtgcaacatt atgattaatc tgattataca ccattttga gcagatctg gaatgaatga
684 catgacctt ccctagagaa taaggatgaa ataactactc attctatgaa cagtacact
685 actttctatt cttagctgt actgtaatt ctttgagtg atagtttac aaattctaa
686 taggtcaaa agcaatctg tctgaataac actggattg tttctgtat ctctgaggtc

687 tattttatgt ttttgctgct acttctgtgg aagtagcttt gaactagttt tactttgaac
688 ttccacgctg aaacatgcta gtgatatcta gaaagggcta attaggtctc atcctttaat
689 gcccttaaa taagctctgc tgatttcag acagggaaagt ctctctatta cactggagct
690 gttttataga taagcaata ttgtatcagg caagataaac caatgcata acaggcattg
691 ccaacctcac tgacacaggg tcatagtga taataatata ctgtactata taatatatca
692 tcttagagg tatgattttt tcatgaaaga taagcttttg gtaatttca ttttaaagtg
693 gactattaa aattggatgc tagagaatca agtttatttt atgtatata ttttctgatt
694 ataagagtaa tatatgttca ttgtaaaaat ttttaaaca cagaaactat atgcaaagaa
695 aaaataaaaa ttatctataa tctcagaacc cagaaatagc cactattaac atttctacg
696 tttttattt tacatagatc atattgtata tagttagat ctttattaat ttttattg
697 aaacttctct ttgtcattat tagtcttcaa aagcatgatt ttaaatggt gttgagtatt
698 ccaccacagg aatgtatcac aactaacccg tcccgttg ttagactagt ttcttattaa
699 tgttgatgaa tgttgtttaa aaataatttt gttgctacat ttactttaat ttcttgact
700 gtaaagagaa gtaattttgc tcttgataa agtattatat taataataaa tctgcctgca
701 acttttgcc ttcttcata atcataaaaa aa
702

703 The yellow highlighted sequences are identical between the two mouse Klotho mRNA
704 sequences. This region is Glycosyl hydrolase-1 1 region+. Two sets of ViewRNA® Probes were
705 used to target 2803-3753 region of canonical mouse Klotho (NM_013823) and 2585-3597 region
706 of mouse Klotho 202 (ENSMUST00000202096.1), respectively. These regions were found to be
707 dissimilar by BLAST, suggesting that each probe set does not bind to the other Klotho mRNA
708 tested.

709

710 ***ImageStream imaging and machine learning-based computational analysis***

711 The flow cytometry for EV imaging was conducted using a 60X objective at a resolution of
712 0.3 $\mu\text{m}^2/\text{pixel}$. The reduced width of the core stream using the 60X magnification reduces the
713 positional space of EVs within the focal plane, thereby increasing the frequency of
714 microscopically focused objects. Filtered sheath buffers were used to ensure the absence of
715 particulates. Samples were acquired using INSPIRE® software with the highest resolution
716 (sensitivity) and lowest speed. All used lasers for fluorochromes employed were used at the
717 optimal power setting.

718 Machine learning algorithms supported by classical computer vision methods were employed
719 on the particles to filter EVs and compute most age-discriminative feature. The computer vision
720 pipeline for filtering operated on the bright-field and side-scatter channels from a database of at
721 least 20,000 samples (~10,000 each of young and aged serum EVs). Successive steps of image
722 morphological operations, histogram-based background noise suppression, iso-data thresholding
723 and h-maxima detection were used to filter spherical and singular EVs that resulted in a final

724 sample set of 13,206 samples. The features used for machine learning algorithms were based on
725 size (area, aspect ratio), signal strength (intensity) and texture (modulation) of the EVs. Size and
726 texture features were extracted from the IDEAS software used to analyze the ImageStream based
727 acquisition of samples. Area and aspect ratio of the EVs indicate how big and circular the EVs
728 are. The texture feature indicates the smoothness or roughness of the EV. This feature explores
729 the dispersion of the protein of interest in the EV. This set of features was augmented with signal
730 strength feature of total intensity, calculated by summing the intensities of all pixels within a
731 binary mask computed using iso-data thresholding after background noise suppression. A total of
732 24 features were used to employ the machine learning algorithms on the filtered database.

733 Cross-correlations were computed for exploratory analysis using Spearman's method as the
734 features were not assumed to be normally distributed. Kernel density estimation was used to
735 compute the density distributions of the intensity channels associated with CD63, CD81 and
736 Klotho mRNA markers extracted from young or aged specimens. In this method, a Gaussian
737 kernel was placed at each data point. The kernel size was computed by Scott's method. The
738 resulting Gaussian mixture estimates the continuous density of the feature. Total Klotho intensity
739 was computed as a sum of intensities from channel 4 and channel 11 images since the probes do
740 not tag same regions of the sequence. Gradient-boosted Decision Trees were used for
741 classification of age with the above-mentioned curated features as input³. Decision tree
742 classifiers are desirable for their ability to measure the importance of the feature to the
743 classification task. Accuracy statistics were reported with 20-fold cross-validation to prevent
744 overfitting.

745

746 *Surface Plasmon Resonance Imaging (SPRi)*

747 Young and aged serum EVs were analyzed by SPRi to study the presence and relative
748 amount of Klotho protein and CD63 on their membranes. First, gold SPRi chips (Horiba
749 Scientific SAS, SPRi-Biochip, Palaiseau, France) were functionalized with antibodies against
750 CD63 (CD63 Antibody, MAB5048, R&D Systems), Klotho (Mouse Klotho Antibody, AF1819,
751 R&D Systems) and IgG (Purified anti-rat IgG1 Antibody, 407402, Biolegend, as negative
752 control). The surface of the chip was coated with a self-assembled monolayer of thiolated PEG
753 molecules for the immobilization of antibodies through EDC/NHS chemistry. Following this, a
754 microspotter (SPRi Arrayer, Horiba) was used to create spots with diameters of 0.7 mm of the

755 selected antibodies in distinct areas of the same SPRi chip. Four spots per antibody were made at
756 ~70% relative humidity at room temperature. The chip was then blocked with a solution of
757 ethanolamine 1 M, pH 9, for 30 min, washed with water and used in SPRi instrument XelPleX
758 (Horiba Scientific SAS).

759 HBS-ET was used as a running buffer (1.5 M NaCl, 100 mM HEPES, 30 mM EDTA, Tween
760 0.5%, pH 7.4). EVs were isolated from 100 μ l of serum by size-exclusion chromatography using
761 qEV column (IZON, qEVsingle) with PBS as running buffer, collecting fractions from 6th to
762 11th and adding protease inhibitors. Aliquots of 500 μ L of young and aged isolated EVs,
763 resuspended in HBS-ET, were injected in the SPRi flow chamber with a flow rate of 10 μ L/min
764 and the SPRi signals were collected and analyzed by using EzSuite software and OriginLab.
765 Sensorgrams were corrected by subtracting the signal related to the anti-rat IgG antibody.

766

767 *Raman Spectroscopy*

768 Young and aged EVs that were isolated by size-exclusion chromatography were concentrated
769 using an ultracentrifugation step (100,000 g x 70min) for 9th to 11th fractions. The concentrated
770 EVs were analyzed by Raman spectroscopy to obtain an overall biochemical (LabRAM, Horiba
771 Jobin Yvon S.A.S. Lille, France) following a previous published protocol (Gualerzi A et al, Sci.
772 Rep, 2017; Gualerzi A et al, JEV, 2019). Briefly, 5 μ l of the concentrated EV suspension was
773 applied on calcium fluoride disks and Raman acquisitions were performed using the following
774 characteristics: (a) 532 nm laser, (b) 50x objective, (c) grating 1800, (d) 400 μ m entrance slit and
775 (e) in the spectral ranges 400-1800 cm^{-1} and 2600-3200 cm^{-1} . A reference sample (Si) at 570.7
776 cm^{-1} was used to calibrate the instrument prior to running the experimental samples. Ten spectra
777 per sample were collected following a line-map from the border of the drop to the edge, with an
778 acquisition time of 30 seconds, following which the acquired data were analyzed through
779 LabSpec6 and OriginLab softwares. First, a despiking (poly 5), baseline correction (fifth order
780 polynomial curve), normalization by unit vector was performed following which multivariate
781 statistical analysis was performed on the spectra. Principal Component Analysis (PCA) was
782 performed for the data reduction identifying the principal components (PCs) that represent the
783 differences in the spectra. Linear discriminant analysis (LDA) was performed by using a small
784 number of PCs (n=15) in order to evaluate the possibility to discriminate the spectra of two

785 groups in statistically significant way (Mann-Whitney Test). PCA was performed using
786 OriginLab PlugIn called "Principal Component Analysis for Spectroscopy".

787

788 ***Administration of EVs to aged cells and silencing Klotho mRNA in EVs***

789 Muscle progenitors from aged or *Klotho*^{-/-} mice were plated at a density of 10,000 cells per
790 well in an 8-well chamber slide for 24 hours. The cells were then exposed to one billion young or
791 aged EVs for a duration of 48 hours.

792 To test whether *Klotho* mRNA may be a driver for *Klotho* modulation within the recipient
793 aged cells and *Klotho*^{-/-} cells, young EVs were treated with non-targeting control scramble or
794 siRNA to *Klotho* for a total of 50 minutes prior to administering them to aged cells. Every billion
795 EVs received 10 µl of transfection reagent (Dharmacon, Dharmafect T-2001-01) and 10 µL of a
796 smart-pool of 5µM non-targeting control (Dharmacon) or siRNA to *Klotho* (Dharmacon). First,
797 the transfection reagent and scramble/siRNA were mixed and incubated in the incubator at 37C
798 for 10 minutes. Following incubation, the EVs were placed on ice for 40 minutes prior to use for
799 an *in vitro* application. Cells receiving the young, aged or treated young EVs were analyzed for
800 MyoD, cardiolipin content and/or *Klotho* expression 48 hours post-administration.

801

802 ***ELISA***

803 Muscle progenitors were plated on an 8 well chamber slide or 12-well plate at a density of
804 8,000 cells or 20,000 cells per well, respectively, prior to treatment with one or two billion EVs.
805 Conditioned media from the samples (untreated aged cells/*Klotho*^{-/-} cells and aged cells/ *Klotho*^{-/-}
806 cells treated with young EVs) were collected 48 hours after treatment.

807 *Klotho* protein levels in media were measured by a colorimetric sandwich enzyme
808 immunoassay (ELISA Kit SEH757Mu, Cloud-Clone Corp, Lot#L170622859) according to
809 manufacturer's instructions. Briefly, 100 µL of standards and samples were added to a 96-well
810 microtiter plate that was pre-coated with a biotin-conjugated antibody specific to *Klotho*. The
811 plate was then incubated for one hour at 37°C following which the samples and standards were
812 removed. A 100 µL of detection reagent A (Biotin-conjugated antibody) was added to each well
813 and incubated at 37°C for one hour. The plates were washed three times with washing buffer
814 provided by the manufacturer. Next, 100 µL of detection reagent B (Avidin conjugated
815 Horseradish-Peroxidase (HRP-avidin)) was added to each well and incubated for 30 minutes at

816 37 °C. The plate was then washed with washing buffer five times. Next, 90µL of
817 tetramethylbenzidine substrate was added to the plate and incubated at 37 °C for 20 minutes. A
818 50 µL sulfuric acid stop solution was then added to terminate the color development reaction.
819 The optical density (OD) of each well was measured at 450 nm. The OD of samples was
820 compared to OD standard curve with known antigen concentrations to determine the
821 concentration of samples. The standard curve had a concentration range from 3.25 pg/mL to 200
822 pg/mL. The data were then normalized to the number of cells per well. Samples were never
823 subjected to freeze-thaw.

824

825 *EV engineering with synthetic mRNA*

826 Aged or Klotho^{+/-} EVs isolated from the serum were transfected with the synthetic Klotho
827 mRNA sequences using Exo-Fect™ exosome transfection reagent from System Biosciences
828 (Cat#EXFT-10A1). Briefly, one billion EVs were treated with 10 µL exofect solution and 1 µg
829 of synthetic Klotho mRNA. The unloaded control EVs were treated with just 10 µL exofect
830 solution. This solution was mixed well by flicking the tube 3 times. Samples were incubated at
831 37°C for 10 minutes. A stopping solution (30 µL) provided in the kit was added to the samples
832 and incubated on ice for 30 minutes to precipitate the EVs. Samples were then centrifuged at
833 16,100 g at 4°C. The supernatants were removed, and samples were re-suspended in culture
834 media (DMEM+20% exosome-free FBS+1% penicillin/streptomycin) and administered to 10,000
835 aged muscle progenitors for 48 hours. The synthetic mRNA used was the Klotho mRNA with
836 RNA length of 3321 NT. The sequence was substituted 25% with Cyanine 5-U and capped
837 (Cap1) using CleanCap™ AG (Trilink Biotechnologies, Lot no. WOTL25007). The opening
838 reading frame used in constructing the synthetic mRNA is:

```
839 ATGCTAGCCCGCGCCCCTCCTCGCCGCCCGCCGCGGCTGGTGCTGCTCCGTTTGCTGTTG  
840 CTGCATCTGCTGCTGCTCGCCCTGCGCGCCCCGCTGCCTGAGCGCTGAGCCGGGTCAGGGC  
841 GCGCAGACCTGGGCTCGCTTCGCGCGCGCTCCTGCCCCAGAGGCCGCTGGCCTCCTCCAC  
842 GACACCTTCCCCGACGGTTTCCTCTGGGCGGTAGGCAGCGCCGCCTATCAGACCGAGGGC  
843 GGCTGGCGACAGCACGGCAAAGGCGCGTCCATCTGGGACACTTTCACCCATCACTCTGGG  
844 GCGGCCCCGTCGACTCCCCGATCGTCGTGGCGCCGTCGGGTGCCCCGTCGCCTCCCCTG  
845 TCCTCCACTGGAGATGTGGCCAGCGATAGTTACAACAACGTCTACCGCGACACAGAGGGG  
846 CTGCGCGAACTGGGGGTCACCCACTACCGCTTCTCCATATCGTGCGCGGGTGTCCCC  
847 AATGGCACCGCGGGCACTCCCAACCGCGAGGGGCTGCGCTACTACCGGCGGCTGCTGGAG  
848 CGGCTGCGGGAGCTGGGCGTGCAGCCGGTGGTTACCCTGTACCATTGGGACCTGCCACAG  
849 CGCCTGCAGGACACCTATGGCGGATGGGCCAATCGCGCCCTGGCCGACCATTTCAGGGAT  
850 TATGCCGAGCTCTGCTTCCGCCACTTCGGTGGTCAGGTCAAGTACTGGATCACCATTGAC  
851 AACCCCTACGTGGTGGCCTGGCACGGGTATGCCACCGGGCGCCTGGCCCCGGGCGTGAGG  
852 GGCAGCTCCAGGCTCGGGTACCTGGTTGCCACAACCTACTTTTGGTCCATGCCAAAGTC
```

853 TGGCATCTCTACAACACCTCTTTCCGCCCCACACAGGGAGGCCGGGTGTCTATCGCCTTA
854 AGCTCCCATTGGATCAATCCTCGAAGAATGACTGACTATAATATCAGAGAATGCCAGAAG
855 TCTCTTGACTTTGTGCTAGGCTGGTTTGCCAAACCCATATTTATTGATGGCGACTACCCA
856 GAGAGTATGAAGAACAACCTCTCGTCTCTTCTGCCTGATTTTACTGAATCTGAGAAGAGG
857 CTCATCAGAGGAACTGCTGACTTTTTTGTCTCTCCTTCGGACCAACCTTGAGCTTTCAG
858 CTATTGGACCCTAACATGAAGTTCGCCAATTGGAGTCTCCCAACCTGAGGCAGCTTCTG
859 TCTTGGATAGATCTGGAATATAACCACCCTCCAATATTTATTGTGGAAAATGGCTGGTTT
860 GTCTCGGGAACCACAAAAGGGATGATGCCAAATATATGTATTATCTCAAGAAGTTCATA
861 ATGGAAACCTTAAAAGCAATCAGACTGGATGGGGTCGACGTCATTGGGTACACCGCGTGG
862 TCGCTCATGGACGGTTTCGAGTGGCATAGGGGCTACAGCATCCGGCGAGGACTCTTCTAC
863 GTTGACTTTCTGAGTCAGGACAAGGAGCTGTTGCCAAAGTCTTCGGCCTTGTCTACCAA
864 AAGCTGATAGAGGACAATGGCTTTCCTCCTTTACCTGAAAACCAGCCCCTTGAAGGGACA
865 TTTCCCTGTGACTTTGCTTGGGGAGTTGTTGACAACACTACGTTCAAGTGGACACTACTCTC
866 TCTCAGTTTACTGACCCGAATGTCTATCTGTGGGATGTGCATCACAGTAAGAGGCTTATT
867 AAAGTAGACGGGTTGTAGCCAAGAAGAAAACCTTACTGTGTTGATTTCTCTGCCATC
868 CGGCCTCAGATAACCTTACTTCGAGAAATGCGGGTCACCCACTTTCGCTTCTCCCTGGAC
869 TGGGCCCTGATCTTGCCTCTGGGTAACCAGACCCAAGTGAACCACACGGTTCTGCACTTC
870 TACCGCTGCATGATCAGCGAGCTGGTGCACGCCAACATCACTCCAGTGGTGGCCCTGTGG
871 CAGCCAGCAGCCCCGCACCAAGGCCTGCCACATGCCCTTGCAAAACATGGGGCCTGGGAG
872 AACCCGCACACTGCTCTGGCGTTTGCAGACTACGCAAACCTGTGTTTTAAAGAGTTGGGT
873 CACTGGGTCAATCTCTGGATCACCATGAACGAGCCAAACACACGGAACATGACCTATCGT
874 GCCGGGCACCACCTCCTGAGAGCCCATGCCTTGGCTTGGCATCTGTACGATGACAAGTTT
875 AGGGCGGCTCAGAAAGGCAAAATATCCATCGCCTTGCAGGCTGACTGGATAGAACCGGCC
876 TGCCCTTTCTCTCAAAATGACAAAGAAGTGGCCGAGAGAGTTTTGGAATTTGATATAGGC
877 TGGCTGGCAGAGCCTATTTTTGGTTCGGGAGATTATCCACGTGTGATGAGGGACTGGCTG
878 AACCAAAAAACAATTTTCTTTTGCCTATTTACCCGAAGATGAAAAAAGCTAGTCCGG
879 GGTTCCTTTGACTTCTGGCGGTGAGTCATTACACCACCATTCTGGTAGACTGGGAAAAG
880 GAGGATCCGATGAAATACAACGATTACTTGGAGGTACAGGAGATGACTGACATCACATGG
881 CTCAACTCTCCAGTCAGGTGGCAGTGGTGCCTTGGGGGCTGCGCAAAGTGCTCAACTGG
882 CTAAGTTCAAGTACGGAGACCTCCCGATGTATGTGACAGCCAATGGAATCGATGATGAC
883 CCCACGCCGAGCAAGACTCACTGAGGATCTATTATATTAAGAATTATGTGAATGAGGCT
884 CTGAAAGCCTACGTGTTGGACGACATCAACCTTTGTGGCTACTTTGCGTATTCACTTAGT
885 GATCGCTCAGTCCCAAGTCTGGCTTTTATCGATATGCTGCGAATCAGTTTGAGCCCAAA
886 CCATCTATGAAACATTACAGGAAAATTATTGACAGCAATGGCTTCTGGGTTCTGGAACA
887 CTGGGAAGGTTTTGTCCAGAAGAATACTGTGTGCACCGAATGTGGATTTTTTCAAACC
888 CGGAAGTCTTTGCTGGTCTTCATCTCGTTTCTGTTTTACTTTTATTATTTCTCTTGCT
889 CTCATTTTTCACTACTCCAAGAAAGGCCAGAGAAGTTATAAGTAA

890

891

892 **References**

- 893 1 Sahu, A. *et al.* Age-related declines in alpha-Klotho drive progenitor cell mitochondrial
894 dysfunction and impaired muscle regeneration. *Nat Commun* **9**, 4859, doi:10.1038/s41467-018-
895 07253-3 (2018).
- 896 2 Yi, L. & Rossi, F. Purification of progenitors from skeletal muscle. *J Vis Exp*, doi:10.3791/2476
897 (2011).
- 898 3 Kuo, D. E. *et al.* Gradient Boosted Decision Tree Classification of Endophthalmitis Versus Uveitis
899 and Lymphoma from Aqueous and Vitreous IL-6 and IL-10 Levels. *J Ocul Pharmacol Ther* **33**, 319-
900 324, doi:10.1089/jop.2016.0132 (2017).

901